AGN-211745

N/A

Report date: 2022/08/11 13:42:05
NME

Base Information

Drug NameAGN-211745
Drug Alias NameAGN-745AGN-211745Sirna-027
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceVascular endothelial growth factor receptor 1 modulators
TargetsVascular endothelial growth factor receptor 1
Therapy Area/IndicationsChoroidal NeovascularizationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPhilippinesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSirna Therapeutics IncAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSirna Therapeutics IncAllergan Plc
Active IndicationsN/A
Inactive IndicationsChoroidal NeovascularizationMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A